研究动态
Articles below are published ahead of final publication in an issue. Please cite articles in the following format: authors, (year), title, journal, DOI.

一项关于针对整体疾病模型的系统综述研究,以辅助医疗资源配置决策。

A systematic review of whole disease models for informing healthcare resource allocation decisions.

发表日期:2023
作者: Huajie Jin, Paul Tappenden, Xiaoxiao Ling, Stewart Robinson, Sarah Byford
来源: Immunity & Ageing

摘要:

整个疾病模型 (WDM) 是大规模的、系统级的模型,可以评估整个护理路径上的多个决策问题。尽管这种类型的模型作为进行经济分析的平台可以提供几个优势,但现有 WDM 的可用性和质量尚不清楚。本系统综述旨在确定现有的 WDM,探讨它们覆盖的疾病领域,对这些模型的质量进行批判性评估,并提供未来研究的建议。于2023年7月23日在多个数据库上进行电子搜索 (MEDLINE、EMBASE、NHS经济评估数据库和医疗技术评估数据库)。两位独立的审稿人选择了包含在内的研究。采用国家健康与护理卓越研究所 (NICE) 对经济评估的评估检查表对研究质量进行评估。对模型特征进行了描述性总结。共鉴定出44个 WDM,其中32个于2010年之后开发。现有 WDM 主要涵盖的疾病领域有心脏病、癌症、获得性免疫缺陷综合症和代谢性疾病。包含的 WDM 的质量普遍较低。常见的限制包括未考虑干预的不良事件 (AEs) 的危害和成本,缺乏概率敏感性分析 (PSA) 和报道不完整。从2010年以来,WDM 的数量有所增加。然而,它们的质量普遍较低,这意味着在重新使用之前可能需要进行重大修改,例如,建模干预的不良事件和纳入PSA。需要报告足够的WDM细节,以便于未来的重复使用/调整。版权所有:©2023 Jin等。本文是一个开放获取文章,根据创作共用许可协议发布,允许在任何媒介中进行任意使用、分发和复制,但必须保留原始作者和出处的署名。
Whole disease models (WDM) are large-scale, system-level models which can evaluate multiple decision questions across an entire care pathway. Whilst this type of model can offer several advantages as a platform for undertaking economic analyses, the availability and quality of existing WDMs is unknown.This systematic review aimed to identify existing WDMs to explore which disease areas they cover, to critically assess the quality of these models and provide recommendations for future research.An electronic search was performed on multiple databases (MEDLINE, EMBASE, the NHS Economic Evaluation Database and the Health Technology Assessment database) on 23rd July 2023. Two independent reviewers selected studies for inclusion. Study quality was assessed using the National Institute for Health and Care Excellence (NICE) appraisal checklist for economic evaluations. Model characteristics were descriptively summarised.Forty-four WDMs were identified, of which thirty-two were developed after 2010. The main disease areas covered by existing WDMs are heart disease, cancer, acquired immune deficiency syndrome and metabolic disease. The quality of included WDMs is generally low. Common limitations included failure to consider the harms and costs of adverse events (AEs) of interventions, lack of probabilistic sensitivity analysis (PSA) and poor reporting.There has been an increase in the number of WDMs since 2010. However, their quality is generally low which means they may require significant modification before they could be re-used, such as modelling AEs of interventions and incorporation of PSA. Sufficient details of the WDMs need to be reported to allow future reuse/adaptation.Copyright: © 2023 Jin et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.